155 related articles for article (PubMed ID: 22110218)
1. Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Tanaka T; Nishiofuku H; Tamamoto T; Sho M; Anai H; Sueyoshi S; Sakaguchi H; Hasegawa M; Nakajima Y; Kichikawa K
Anticancer Res; 2011 Nov; 31(11):3909-12. PubMed ID: 22110218
[TBL] [Abstract][Full Text] [Related]
2. [Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Nishiofuku H; Tanaka T; Anai H; Sueyoshi S; Yamamoto K; Morimoto K; Maeda S; Masada T; Sho M; Nakajima Y; Tamamoto T; Hasegawa M; Sakaguchi H; Kichikawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2315-8. PubMed ID: 21224558
[TBL] [Abstract][Full Text] [Related]
3. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Tanaka T; Sho M; Nishiofuku H; Sakaguchi H; Inaba Y; Nakajima Y; Kichikawa K
AJR Am J Roentgenol; 2012 Jun; 198(6):1445-52. PubMed ID: 22623561
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
Takeda Y; Nakamori S; Eguchi H; Kobayashi S; Marubashi S; Tanemura M; Konishi K; Yoshioka Y; Umeshita K; Mori M; Doki Y; Nagano H
Jpn J Clin Oncol; 2014 Dec; 44(12):1172-80. PubMed ID: 25425728
[TBL] [Abstract][Full Text] [Related]
6. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
7. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
[TBL] [Abstract][Full Text] [Related]
8. Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):157-62. PubMed ID: 22543205
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
[TBL] [Abstract][Full Text] [Related]
10. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
[TBL] [Abstract][Full Text] [Related]
12. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
[TBL] [Abstract][Full Text] [Related]
13. Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Taira K; Boku N; Fukutomi A; Onozawa Y; Hironaka S; Yoshino T; Yasui H; Yamazaki K; Taku K; Hashimoto T; Nishimura T
J Gastroenterol; 2008; 43(11):875-80. PubMed ID: 19012041
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Huang J; Robertson JM; Margolis J; Balaraman S; Gustafson G; Khilanani P; Nadeau L; Jury R; McIntosh B
Radiother Oncol; 2011 May; 99(2):114-9. PubMed ID: 21621866
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of radiotherapy for locally advanced pancreatic cancer.
Sawaki A; Hoki N; Ito S; Matsumoto K; Mizuno N; Hara K; Takagi T; Kobayashi Y; Sawai Y; Kawai H; Tajika M; Nakamura T; Yamao K
J Gastroenterol; 2009; 44(12):1209-14. PubMed ID: 19705054
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
Igarashi H; Ito T; Kawabe K; Hisano T; Arita Y; Kaku T; Takayanagi R
World J Gastroenterol; 2008 Sep; 14(34):5311-5. PubMed ID: 18785284
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
20. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
